Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women

This study was conducted to compare oral contraceptive (OC) pharmacokinetics (PK) in normal-weight [body mass index (BMI) 19.0–24.9] and obese (BMI 30.0–39.9) women. During the third week of the third cycle of OC use, we admitted 15 normal-weight and 15 obese women for collection of 12 venous specim...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Contraception (Stoneham) Ročník 81; číslo 6; s. 474 - 480
Hlavní autori: Westhoff, Carolyn L., Torgal, Anupama H., Mayeda, Elizabeth R., Pike, Malcolm C., Stanczyk, Frank Z.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: New York, NY Elsevier Inc 01.06.2010
Elsevier
Predmet:
Adult
Biological and medical sciences
Birth control
BMI
Body Mass Index
Combined oral contraceptives
Contraceptives, Oral, Combined - blood
Contraceptives, Oral, Combined - pharmacokinetics
Contraceptives, Oral, Combined - pharmacology
Estradiol - blood
Ethinyl Estradiol - blood
Ethinyl Estradiol - pharmacokinetics
Female
Genital system. Reproduction
Gynecology. Andrology. Obstetrics
Half-Life
Hormonal contraception
Humans
Levonorgestrel - blood
Levonorgestrel - pharmacokinetics
Medical sciences
Menstrual Cycle - blood
Metabolic diseases
Obesity
Obesity - blood
Obesity - physiopathology
Obstetrics and Gynecology
Organ Size
Ovarian Follicle - anatomy & histology
Ovarian Follicle - diagnostic imaging
Ovarian Follicle - drug effects
Ovulation Inhibition - blood
Ovulation Inhibition - drug effects
Pharmacokinetics
Pharmacology. Drug treatments
Progesterone - blood
Radioimmunoassay
Ultrasonography
Young Adult
Obesity
Pharmacokinetics
Combined oral contraceptives
BMI
Ethinylestradiol
Human
Estrogen
Nutrition disorder
Levonorgestrel
Oral administration
Progestagen
Female
Contraceptive
Woman
Nutritional status
ISSN:0010-7824, 1879-0518, 1879-0518
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:This study was conducted to compare oral contraceptive (OC) pharmacokinetics (PK) in normal-weight [body mass index (BMI) 19.0–24.9] and obese (BMI 30.0–39.9) women. During the third week of the third cycle of OC use, we admitted 15 normal-weight and 15 obese women for collection of 12 venous specimens over 24 h. Using radioimmunoassay techniques, we measured levels of ethinyl estradiol (EE) and levonorgestrel (LNG). During the same cycle, women underwent twice-weekly sonography to assess ovarian follicular development and blood draws to measure endogenous estradiol (E2) and progesterone levels. Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg⁎h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups. The similar, but smaller, differences in their LNG levels for AUC and maximum values (Cmax) were not statistically significant. While peak values differed somewhat, the LNG trough levels were similar for obese and normal-weight women (2.6 and 2.5 ng/mL, respectively). Women with greater EE AUC had smaller follicular diameters (p=.05) and lower E2 levels (p=.04). While follicular diameters tended to be larger among obese women, these differences were not statistically significant. OC hormone peak levels are lower among obese women compared to normal-weight women, but their trough levels are similar. In this small study, the observed PK differences did not translate into more ovarian follicular activity among obese OC users.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0010-7824
1879-0518
1879-0518
DOI:10.1016/j.contraception.2010.01.016